Enzymatically Switchable Pyroptosis-Inducing Polymer Conjugate to Coordinate Host Immune Responses in Cancer

Torsha Ghosh1, Jueun Jeon1, Van Hieu Duong1

  • 1School of Chemical Engineering, College of Engineering, Sungkyunkwan University, Suwon, 16419, Republic of Korea.

Insights

A novel polymer conjugate, EPIC, precisely triggers pyroptosis (programmed cell death) in cancer cells. This approach enhances anti-tumor immunity and shows promise for effective cancer immunotherapy, leading to durable tumor remission.

Area of Science:

  • Biomedical Engineering
  • Immunology
  • Oncology

Background:

  • Gasdermin-D-mediated pyroptosis is crucial for immunity and a potential cancer immunotherapy target.
  • Controlling pyroptosis spatiotemporally in cancer treatment remains a significant challenge.

Purpose of the Study:

  • To develop a novel polymer conjugate (EPIC) for precise, enzyme-activated pyroptosis induction in cancer cells.
  • To evaluate EPIC's efficacy as a cancer immunotherapy agent, alone and in combination with anti-PD-1 therapy.

Main Methods:

  • An Enzymatically switchable Pyroptosis-Inducing polymer Conjugate (EPIC) was designed to activate via Cathepsin B in cancer cells.
  • EPIC induces chemiluminescence resonance energy transfer (CRET) leading to reactive oxygen species generation and lysosomal disruption.
  • In vitro and in vivo studies assessed EPIC's ability to trigger pyroptosis, activate immune cells, and treat tumors in mice.

Main Results:

  • EPIC selectively triggered pyroptosis in cancer cells, releasing damage-associated molecular patterns and cytokines.
  • In tumor-bearing mice, EPIC promoted dendritic cell maturation and NK cell activity.
  • Combination therapy with EPIC and anti-PD-1 antibody significantly enhanced anti-tumor immunity, leading to durable remission and complete tumor regression in over 50% of mice.

Conclusions:

  • EPIC serves as a versatile nanoplatform for precise cancer immunotherapy.
  • EPIC demonstrates significant potential for effective cancer treatment by inducing immunogenic cell death and enhancing anti-tumor immune responses.

Related Concept Videos